

ALEXION PHARMACEUTICALS INC  
Form 4  
August 01, 2013

**FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BELL LEONARD**

2. Issuer Name and Ticker or Trading Symbol  
**ALEXION PHARMACEUTICALS INC [ALXN]**

5. Relationship of Reporting Person(s) to Issuer  
(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
**07/30/2013**

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
**CEO**

**C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE**

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**CHESHIRE, CT 06410**

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3)            | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--------------------------------------|--|--------------------------------|---|---|--|---|
|  |                                      |  | Code                           | V   | Amount (A) or (D) Price   |  |   |
| Common Stock, par value \$0.0001 per share | 07/30/2013                           |  | S                              |   | 37,103 (1) D 109.56 (2) 1,355,222   | D  |   |
| Common Stock, par value \$0.0001 per share | 07/30/2013                           |  | S                              |   | 50,967 (1) D 110.53 (3) 1,304,255   | D  |   |

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

|                         |            |   |                              |   |                                     |           |   |
|-------------------------|------------|---|------------------------------|---|-------------------------------------|-----------|---|
| Common Stock, par value | 07/30/2013 | S | <u>6,125</u> <sup>(1)</sup>  | D | \$<br><u>111.04</u> <sup>(4)</sup>  | 1,298,130 | D |
| \$\$.0001 per share     |            |   |                              |   |                                     |           |   |
| Common Stock, par value | 07/30/2013 | S | <u>4,200</u> <sup>(1)</sup>  | D | \$<br><u>112.56</u> <sup>(5)</sup>  | 1,293,930 | D |
| \$\$.0001 per share     |            |   |                              |   |                                     |           |   |
| Common Stock, par value | 07/30/2013 | S | <u>200</u> <sup>(1)</sup>    | D | \$<br><u>113.12</u>                 | 1,293,730 | D |
| \$\$.0001 per share     |            |   |                              |   |                                     |           |   |
| Common Stock, par value | 07/30/2013 | S | <u>100</u> <sup>(1)</sup>    | D | \$<br><u>114.85</u>                 | 1,293,630 | D |
| \$\$.0001 per share     |            |   |                              |   |                                     |           |   |
| Common Stock, par value | 07/30/2013 | S | <u>27,900</u> <sup>(1)</sup> | D | \$<br><u>116.11</u> <sup>(6)</sup>  | 1,265,730 | D |
| \$\$.0001 per share     |            |   |                              |   |                                     |           |   |
| Common Stock, par value | 07/30/2013 | S | <u>10,817</u> <sup>(1)</sup> | D | \$<br><u>117.24</u> <sup>(7)</sup>  | 1,254,913 | D |
| \$\$.0001 per share     |            |   |                              |   |                                     |           |   |
| Common Stock, par value | 07/30/2013 | S | <u>17,376</u> <sup>(1)</sup> | D | \$<br><u>118.27</u> <sup>(8)</sup>  | 1,237,537 | D |
| \$\$.0001 per share     |            |   |                              |   |                                     |           |   |
| Common Stock, par value | 07/30/2013 | S | <u>10,001</u> <sup>(1)</sup> | D | \$<br><u>119.74</u> <sup>(9)</sup>  | 1,227,536 | D |
| \$\$.0001 per share     |            |   |                              |   |                                     |           |   |
| Common Stock, par value | 07/30/2013 | S | <u>39,099</u> <sup>(1)</sup> | D | \$<br><u>120.09</u> <sup>(10)</sup> | 1,188,437 | D |
| \$\$.0001 per share     |            |   |                              |   |                                     |           |   |
|                         | 07/30/2013 | S |                              | D |                                     | 1,182,325 | D |

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

|   |            |                     |                      |   |    |        |           |   |  |  |
|---|------------|---------------------|----------------------|---|----|--------|-----------|---|--|--|
| Common<br>Stock, par<br>value<br>\$.0001 per<br>share |            | 6,112<br><u>(1)</u> | \$                   |   |    |        |           |   |  |  |
|   |            |                     |                      |   |    |        |           |   |  |  |
| Common<br>Stock, par<br>value<br>\$.0001 per<br>share | 07/30/2013 | S                   | 2,737<br><u>(12)</u> | D | \$ | 110.86 | 1,179,588 | D |  |  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.** SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|--|
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|--|

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |         |       |
|--|---------------|-----------|---------|-------|
|  | Director      | 10% Owner | Officer | Other |
| BELL LEONARD<br>C/O ALEXION PHARMACEUTICALS INC<br>352 KNOTTER DRIVE<br>CHESHIRE, CT 06410 | X             |           | CEO     |       |

## Signatures

/s/ Leonard Bell 08/01/2013

\*\*Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The transaction reported by this Form 4 is made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.
- (2) This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$108.97 - \$109.97. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- (3) This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$109.97 - \$110.97. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- (4) This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$110.97 - \$111.97. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- (5) This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$111.98 - \$112.98. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- (6) This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$115.88 - \$116.88. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- (7) This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$116.91 - \$117.91. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- (8) This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$117.92 - \$118.92. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- (9) This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$118.96 - \$119.96. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- (10) This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$119.98 - \$120.98. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- (11) This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$121.00 - \$122.00. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- (12) This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.